Taysha Gene Therapies Stock Today
| TSHA Stock | USD 1.53 0.05 3.16% |
Performance0 of 100
| Odds Of DistressOver 85
|
Taysha Gene is trading at 1.53 as of the 23rd of January 2025, a 3.16 percent decrease since the beginning of the trading day. The stock's open price was 1.58. Taysha Gene has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 23rd of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of September 2020 | Category Healthcare | Classification Health Care |
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company was incorporated in 2019 and is based in Dallas, Texas. The company has 204.94 M outstanding shares of which 25.88 M shares are at this time shorted by private and institutional investors with about 7.38 trading days to cover. More on Taysha Gene Therapies
Moving against Taysha Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Taysha Stock Highlights
| CEO Chairman | Sean Nolan | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsTaysha Gene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Taysha Gene's financial leverage. It provides some insight into what part of Taysha Gene's total assets is financed by creditors.
| |||||
Taysha Gene Therapies (TSHA) is traded on NASDAQ Exchange in USA. It is located in 3000 Pegasus Park Drive, Dallas, TX, United States, 75247 and employs 52 people. Taysha Gene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 313.56 M. Taysha Gene Therapies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 204.94 M outstanding shares of which 25.88 M shares are at this time shorted by private and institutional investors with about 7.38 trading days to cover.
Taysha Gene Therapies currently holds about 66.24 M in cash with (73.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Taysha Gene Probability Of Bankruptcy
Ownership AllocationTaysha Gene Therapies shows a total of 204.94 Million outstanding shares. The majority of Taysha Gene Therapies outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Taysha Gene to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Taysha Gene Therapies. Please pay attention to any change in the institutional holdings of Taysha Gene Therapies as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Taysha Ownership Details
Taysha Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tybourne Capital Management (hk) Ltd | 2024-09-30 | 3.7 M | |
| Geode Capital Management, Llc | 2024-09-30 | 3.6 M | |
| State Street Corp | 2024-09-30 | 3.5 M | |
| Polar Capital Holdings Plc | 2024-09-30 | 3 M | |
| Jpmorgan Chase & Co | 2024-09-30 | 3 M | |
| Citadel Advisors Llc | 2024-09-30 | 2.9 M | |
| Deutsche Bank Ag | 2024-09-30 | 2.6 M | |
| Ghost Tree Capital, Llc | 2024-09-30 | 2.1 M | |
| Longwood Capital Partners Llc | 2024-09-30 | 2.1 M | |
| Fmr Inc | 2024-09-30 | 18.7 M | |
| Venbio Select Advisor Llc | 2024-09-30 | 18.6 M |
Taysha Gene Historical Income Statement
Taysha Stock Against Markets
Taysha Gene Corporate Management
| Greg Gara | VP Manufacturing | Profile | |
| Tracy Porter | Chief Officer | Profile | |
| Jim Rouse | Chief Officer | Profile | |
| R II | President, Founder | Profile | |
| FFPM MSc | Chief RD | Profile | |
| Steven Gray | Chief Program | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taysha Gene Therapies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taysha Gene. If investors know Taysha will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taysha Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.63 | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets | Return On Equity |
The market value of Taysha Gene Therapies is measured differently than its book value, which is the value of Taysha that is recorded on the company's balance sheet. Investors also form their own opinion of Taysha Gene's value that differs from its market value or its book value, called intrinsic value, which is Taysha Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taysha Gene's market value can be influenced by many factors that don't directly affect Taysha Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taysha Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taysha Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taysha Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.